10-Q: CV Sciences Reports Declining Revenue, Increased Net Loss

CV Sciences, Inc. (CVSI) filed its Q2 2026 10-Q, revealing a 17.5% year-over-year revenue decline and a widening net loss, raising going concern doubts.

Summary

• CV Sciences, Inc. reported a net loss of $775,000 for the three months ended June 30, 2026, compared to a net loss of $261,000 for the same period in 2025.
• For the six months ended June 30, 2026, the net loss was $1,418,000, an increase from $370,000 in the prior year period.
• Product sales decreased by 17.5% to $2.985 million in Q2 2026 compared to $3.620 million in Q2 2025.
• Total assets decreased from $6.962 million at December 31, 2025, to $6.521 million at June 30, 2026.
• The company has an accumulated deficit of $89.4 million as of June 30, 2026, and generated only $0.1 million in cash flow from operations for the six months ended June 30, 2026, raising substantial doubt about its ability to continue as a going concern.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to declining revenues, increasing net loss, and significant going concern risks, despite some cost-saving measures.

Positives

• Cost of goods sold decreased by 13.6% in Q2 2026 compared to Q2 2025, primarily due to lower unit sales.
• Selling, general, and administrative (SG&A) expenses decreased by 10% in Q2 2026 compared to Q2 2025, driven by reductions in sales, general, and administrative costs.
• The company is actively managing costs, including reductions in employee headcount and vendor spending, and delaying drug development expenses.
• 44.3% of net revenue in Q2 2026 was from new products launched since January 1, 2023, indicating product innovation.

Negatives

• Net sales decreased by 17.5% to $2.985 million in Q2 2026 compared to $3.620 million in Q2 2025, driven by lower sales volume due to restrictive state regulations and out-of-stock issues.
• Gross profit decreased by 21.4% in Q2 2026 compared to Q2 2025.
• Gross margin declined from 50.9% in Q2 2025 to 48.6% in Q2 2026, attributed to higher freight, product mix, and increased costs for acquired businesses.
• The company's accumulated deficit increased to $89.4 million as of June 30, 2026.
• Cash flow from operations was only $0.1 million for the six months ended June 30, 2026, indicating a significant liquidity concern.
• The company's ability to continue as a going concern is in substantial doubt due to its financial performance and accumulated deficit.

Risks

• Restrictive state regulations in the hemp-derived cannabinoid market are negatively impacting sales and are expected to continue to do so.
• The evolving regulatory environment for hemp-derived cannabinoid products, including potential changes to the definition of hemp and THC limits, could materially adversely impact the company's business, results of operations, and cash flows.
• Intense competition from both licensed and illicit market operators in a fragmented and highly competitive market.
• The company's dependence on additional investment capital to fund operations and growth initiatives, with no assurance of successful capital raising.
• Potential adverse impacts from general economic conditions, inflation, and rising interest rates.
• Uncertainty regarding the development, sale, and use of CBD products in the United States due to a lack of clear federal regulatory framework.
• Trade policies and tariffs, particularly on imports from China, could increase costs and impact sales and profitability.

Future Outlook

Management anticipates dependence on additional investment capital to fund operations and growth initiatives. The company intends to raise additional funds through capital markets, debt issuance, and lines of credit. The company is evaluating the potential impact of evolving hemp-derived cannabinoid legislation, which could materially adversely impact its business, results of operations, and cash flows. Management is implementing strategic cost reductions and may take further actions to ensure business success.

Management Comments

• Management anticipates that the Company will be dependent, for the near future, on additional investment capital to fund operations, growth initiatives and will continue to make and implement strategic cost reductions, including reductions in employee headcount, vendor spending, and delaying expenses related to its drug development activities.
• The Company intends to position itself so that it will be able to raise additional funds through the capital markets, issuance of debt, and/or securing lines of credit.
• While management cannot reasonably estimate the financial effect of this legislation at this time, it could have a material adverse impact on the Company's business, results of operations, and cash flows.
• The Company's financial operating results and accumulated deficit, amongst other factors, raise substantial doubt about the Company's ability to continue as a going concern.

Industry Context

StockSavvy.ai notes that CV Sciences operates in the highly competitive and evolving hemp-derived cannabinoid market, which is significantly impacted by a patchwork of state regulations and a lack of clear federal guidance. This creates a challenging environment for growth and revenue generation, as evidenced by the company's declining sales and increased net loss.

Comparison to Industry Standards

• The filing does not provide specific comparative data against industry benchmarks or named competitors.
• The company mentions SPINS data indicating its +PlusCBD brand is a top-selling hemp extract brand in the natural products market, but does not quantify market share or growth rates relative to competitors.
• The company's gross margin of 48.6% in Q2 2026 is presented in isolation, without comparison to typical margins in the nutraceutical or CBD product sectors.

Legal Proceedings

• A putative class action complaint (Colette Complaint) alleging product labeling violated the Food, Drug, and Cosmetic Act of 1938 remains stayed pending FDA rulemaking on CBD ingestible products. The FDA has indicated it does not intend to pursue such rulemaking, and the case remains stayed.
• The company initiated arbitration against its former legal counsel, Procopio, asserting claims related to advice provided on payroll tax withholding for stock settlements. The evidentiary hearing is scheduled for May 17, 2027.

Related Party Transactions

• The company has a history of stock-based compensation and settlement agreements with its former President and CEO, Michael Mona Jr. (Mona).
• Unvested stock options for Mona continue to vest based on company milestones related to drug development.
• A dispute arose regarding payroll tax withholding for RSU settlements to Mona, leading to arbitration against former legal counsel Procopio.
• The company derecognized a receivable and contingent liability related to Mona's unremitted personal income taxes for 2019, as statutes of limitations expired.

Stakeholder Impact

• Shareholders face continued financial pressure due to declining revenues, increasing losses, and substantial going concern risks.
• Employees may be impacted by ongoing cost reductions, including potential headcount reductions.
• Suppliers may face challenges if the company's liquidity issues worsen.
• Creditors could be impacted by the company's ability to meet its debt obligations, especially given the going concern uncertainty.

Next Steps

• Continue to implement strategic cost reductions, including headcount and vendor spending.
• Delay expenses related to drug development activities.
• Assess and potentially modify product formulations, labeling, and compliance measures in response to evolving hemp-derived cannabinoid legislation.
• Continue to innovate new products, build brand awareness, and invest in business strategy.
• Evaluate inbound and outbound merger, sale, acquisition, or other opportunities.
• Seek to raise additional funds through capital markets, debt issuance, and/or securing lines of credit.

Key Dates

Recommendation

The filing indicates a worsening financial situation with declining revenues, increasing net losses, and significant going concern risks. The company's ability to continue operations is in substantial doubt, and it is heavily reliant on future capital raises, which are not guaranteed. The evolving regulatory landscape for CBD products adds further uncertainty. These factors suggest a high risk for investors.

Keywords

CV Sciences, Hemp Extracts, CBD Products, Nutraceuticals, Plant-based Foods, Quarterly Report, Financial Statements, Regulatory Environment